JP7258038B6 - Ｂ７－ｈ４抗体の投薬計画 - Google Patents

Ｂ７－ｈ４抗体の投薬計画 Download PDF

Info

Publication number
JP7258038B6
JP7258038B6 JP2020544277A JP2020544277A JP7258038B6 JP 7258038 B6 JP7258038 B6 JP 7258038B6 JP 2020544277 A JP2020544277 A JP 2020544277A JP 2020544277 A JP2020544277 A JP 2020544277A JP 7258038 B6 JP7258038 B6 JP 7258038B6
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544277A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019165075A5 (https=
JP7258038B2 (ja
JP2021513997A5 (https=
JP2021513997A (ja
Inventor
サンディープ ピー． イナムダー，
ヘレン エル． コリンズ，
シャン ジャン，
ホン シャン，
Original Assignee
ファイヴ プライム セラピューティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイヴ プライム セラピューティクス インク filed Critical ファイヴ プライム セラピューティクス インク
Publication of JP2021513997A publication Critical patent/JP2021513997A/ja
Publication of JPWO2019165075A5 publication Critical patent/JPWO2019165075A5/ja
Publication of JP2021513997A5 publication Critical patent/JP2021513997A5/ja
Priority to JP2023060944A priority Critical patent/JP2023089063A/ja
Publication of JP7258038B2 publication Critical patent/JP7258038B2/ja
Application granted granted Critical
Publication of JP7258038B6 publication Critical patent/JP7258038B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020544277A 2018-02-21 2019-02-21 Ｂ７－ｈ４抗体の投薬計画 Active JP7258038B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060944A JP2023089063A (ja) 2018-02-21 2023-04-04 Ｂ７－ｈ４抗体の投薬計画

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862633527P 2018-02-21 2018-02-21
US62/633,527 2018-02-21
US201962802100P 2019-02-06 2019-02-06
US62/802,100 2019-02-06
PCT/US2019/018963 WO2019165075A1 (en) 2018-02-21 2019-02-21 B7-h4 antibody dosing regimens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060944A Division JP2023089063A (ja) 2018-02-21 2023-04-04 Ｂ７－ｈ４抗体の投薬計画

Publications (5)

Publication Number Publication Date
JP2021513997A JP2021513997A (ja) 2021-06-03
JPWO2019165075A5 JPWO2019165075A5 (https=) 2022-03-01
JP2021513997A5 JP2021513997A5 (https=) 2022-03-01
JP7258038B2 JP7258038B2 (ja) 2023-04-14
JP7258038B6 true JP7258038B6 (ja) 2023-04-25

Family

ID=65686103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544277A Active JP7258038B6 (ja) 2018-02-21 2019-02-21 Ｂ７－ｈ４抗体の投薬計画
JP2023060944A Pending JP2023089063A (ja) 2018-02-21 2023-04-04 Ｂ７－ｈ４抗体の投薬計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060944A Pending JP2023089063A (ja) 2018-02-21 2023-04-04 Ｂ７－ｈ４抗体の投薬計画

Country Status (13)

Country Link
US (3) US20210070862A1 (https=)
EP (1) EP3755719A1 (https=)
JP (2) JP7258038B6 (https=)
KR (1) KR102863169B1 (https=)
CN (1) CN111868089B (https=)
AU (1) AU2019226009B2 (https=)
BR (1) BR112020016990A2 (https=)
CA (1) CA3091161A1 (https=)
IL (1) IL276623A (https=)
MA (1) MA51902A (https=)
MX (1) MX2020008730A (https=)
SG (1) SG11202007820QA (https=)
WO (1) WO2019165075A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672990A1 (en) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
JP2021514379A (ja) * 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
WO2020081497A1 (en) * 2018-10-15 2020-04-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
JP2024501894A (ja) 2021-01-04 2024-01-16 メルサナ セラピューティクス インコーポレイテッド Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500853A (ja) 2017-08-25 2021-01-14 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体及びその使用方法
JP2021514379A (ja) 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
CA2478297C (en) 2002-03-19 2013-05-14 Plant Research International B.V. Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
CN103540600B (zh) 2003-01-22 2017-12-01 罗氏格黎卡特股份公司 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
JP2008539753A (ja) 2005-05-09 2008-11-20 グリクアート バイオテクノロジー アクチェンゲゼルシャフト 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
JP6120848B2 (ja) * 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
AU2013361275B2 (en) * 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500853A (ja) 2017-08-25 2021-01-14 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体及びその使用方法
JP2021514379A (ja) 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤

Also Published As

Publication number Publication date
CN111868089A (zh) 2020-10-30
JP2023089063A (ja) 2023-06-27
MA51902A (fr) 2021-05-26
AU2019226009B2 (en) 2025-11-20
AU2019226009A1 (en) 2020-09-03
SG11202007820QA (en) 2020-09-29
WO2019165075A1 (en) 2019-08-29
US20210070862A1 (en) 2021-03-11
EP3755719A1 (en) 2020-12-30
JP7258038B2 (ja) 2023-04-14
MX2020008730A (es) 2020-12-07
US20230287123A1 (en) 2023-09-14
KR20200123169A (ko) 2020-10-28
US20240317864A1 (en) 2024-09-26
BR112020016990A2 (pt) 2021-02-23
KR102863169B1 (ko) 2025-09-22
CN111868089B (zh) 2025-08-22
CA3091161A1 (en) 2019-08-29
IL276623A (en) 2020-09-30
JP2021513997A (ja) 2021-06-03

Similar Documents

Publication Publication Date Title
US12435145B2 (en) B7-H4 antibody formulations
US20240317864A1 (en) B7-h4 antibody dosing regimens
TWI835885B (zh) 用於癌症之組合療法
US9067996B2 (en) Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN114630679A (zh) 抗garp抗体和免疫调节剂的组合
US20230322928A1 (en) Treatment methods using ctla-4 and pd-1 bispecific antibodies
EA048025B1 (ru) Комбинированная терапия онкологического заболевания
HK40117614A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法
HK40036127B (zh) B7-h4抗体给药方案
HK40036127A (en) B7-h4 antibody dosing regimens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230404

R150 Certificate of patent or registration of utility model

Ref document number: 7258038

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250